Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme by Gastelurrutia, Paloma et al.
Potential role for clinical calibration to increase
engagement with and application of home
telemonitoring: a report from the HeartCycle
programme
Paloma Gastelurrutia1, Josep Lupón2,3, Mar Domingo2, Wim Stut4, Silviu Dovancescu4, John Cleland5, Lutz
Frankenstein6, Antoni Bayes-Genis1,2,3* and on behalf of the HeartCycle Programme Investigators
1ICREC Research Program, Fundació Institut d´Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain; 2Cardiology Service, Hospital Universitari
Germans Trias i Pujol, Badalona, Spain; 3Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; 4Philips Research, Eindhoven, The Netherlands;
5National Heart and Lung Institute, Hareﬁeld Hospital, Imperial College, London, UK; 6Heidelberg University Hospital, Heidelberg, Germany
Abstract
Aims There is a need for alternative strategies that might avoid recurrent admissions in patients with heart failure. home
telemonitoring (HTM) to monitor patient’s symptoms from a distance may be useful. This study attempts to assess changes
in HTM vital signs in response to daily life activities (variations in medication, salt intake, exercise, and stress) and to establish
which variations affect weight, blood pressure, and heart rate.
Methods and results We assessed 76 patients with heart failure (mean age 76 ± 10.8 years, 75% male, mainly in NYHA class
II/III and from ischaemic aetiology cause). Patients were given a calendar of interventions scheduling activities approximately
twice a week before measuring their vital signs. Eating salty food or a large meal were the activities that had a signiﬁcant
impact on weight gain (+0.3 kg; P< 0.001 and P = 0.006, respectively). Exercise and skipping a dose of medication other than
diuretics increased heart rate (+3 bpm, P = 0.001 and almost +2 bpm, P = 0.016, respectively).
Conclusions Our HTM system was able to detect small changes in vital signs related to these activities. Further studies
should assess if providing such a schedule of activities might be useful for patient education and could improve long-term
adherence to recommended lifestyle changes.
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Introduction
Heart failure (HF) is a clinical syndrome with a high preva-
lence, rising to more than 10% among people over the age
of 70 years.1 What is more, in Europe, 24% of patients are
readmitted within 12weeks of discharge.2 Some of the most
common causes of readmission are deﬁcient treatment ad-
herence, no or too-late identiﬁcation of disease destabiliza-
tion signs, and hospital discharge without complete
resolution of congestion.3 As HF prevalence keeps rising,
there is an urgent need for alternative strategies that might
avoid recurrent admissions, and novel technologies such as
home telemonitoring (HTM) to monitor patient’s symptoms
from a distance may be useful.4
The effects of variations in daily routine on HTM mea-
surements are unknown and might provide additional in-
sights into physiological responsiveness and disease
stability for individual patients. Providing patients with pro-
grammed variations in their daily routine might provide in-
formation on the sensitivity of individual patients to
common interventions, such as dietary or medication
compliance.
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This study attempts to assess changes in HTM vital signs
in response to daily life activities (variations in medication,
salt intake, exercise, and stress) and to establish which
variations affect weight, blood pressure (BP), and heart
rate (HR).
Methods
HeartCycle is a programme that aims to improve the quality of
life for cardiac patients by monitoring their condition and in-
volving them in the daily management of their disease as well
Figure 1 Heart failure trial phases of the HeartCycle programme.
Figure 2 Study ﬂow chart.
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as facilitating clinicians tomonitor relevant data for prescribing
personalized therapies and lifestyle recommendations.5Oneof
its parts is the HF trial (Figure 1), which aims to investigate the
HeartCycle’s HF Management system (HFM), a 3rd generation
HTM system that provides feedback and an educational pro-
gramme about lifestyle and symptoms management. It is built
onPhilips’existing commercialMOTIVAproduct that integrates
weight scales and a sphygmomanometer thatmeasures BP and
HR. The MOTIVA system has been described elsewhere.6 The
trial took place in three European sites (University Hospital Cas-
tle Hill, Hull, UK; University Hospital Heidelberg, Heidelberg,
Germany; University Hospital Germans Trias i Pujol, Barcelona,
Spain) andwas conducted in four phases. The present study fo-
cuses on Phase CofHeartCycle’sHF trial and tries to assess how
variations of everyday routine alter vital signs.
Consecutive patients were asked to participate in the
HeartCycle HTM programme. Inclusion criteria included the
following: (1) a clinical diagnosis of HF, (2) requiring treatment
with at least 40mg/day of furosemide or equivalent, (3) evi-
dence of advanced or unstable disease (mainly admission to
hospital for or complicated by HF currently or within the pre-
vious 60 days or out-patients with persistent NYHA III/IV
symptoms), (4) an elevated NT-proBNP (>1000 pg/mL if in si-
nus rhythm or>2000 pg/mL if not). Patients unwilling to com-
ply with the protocol, with rapidly reversible causes of HF
(such as severe anaemia, thyrotoxicosis, or admission with
rapid atrial ﬁbrillation with good ventricular function), with in-
ability in the investigators’ opinion to operate the HTM sys-
tem, unable to communicate in the local language, aged
<18 years and vulnerable groups were excluded.
Patients were asked to report symptoms and measure
weight, HR, and BP on a daily basis. After a period of stabili-
zation and diuretic optimization (Phase A and B, respectively),
patients entered the 2month follow-up Phase C. Patients
Table 1. Mean values and change between day of activity and the day before the activity for the different measurements performed
Activity Measurement
Day before activity Activity day
Change [95% IC] P-valueMean value Mean value
After salty food SBP 110.5 108.8 1.74 [4.05; 0.57] 0.14
DBP 67.7 66.1 1.55 [3.12; 0.01] 0.05
HR 66.5 67.2 0.74 [0.66; 2.14] 0.30
Weight 84.0 84.3 0.28 [0.14; 0.43] <0.001
After skipping a dose of diuretic SBP 111.1 112.1 1.05 [2.13; 4.23] 0.51
DBP 66.6 66.6 0.08 [1.62; 1.47] 0.92
HR 66.0 67.1 1.10 [0.16; 2.36] 0.09
Weight 84.2 84.3 0.13 [0.03;0.29] 0.10
While listening to loud and irritating noise SBP 110.7 111.4 0.76 [2.05; 3.58] 0.59
DBP 67.0 68.0 1.04 [0.74; 2.82] 0.25
HR 66.0 67.2 1.26 [0.52; 3.03] 0.16
Weight 83.9 84.0 0.13 [0.03; 0.29] 0.10
After tea or coffee SBP 112.6 113.1 0.44 [3.14; 4.02] 0.81
DBP 68.7 68.0 0.71 [2.51; 1.10] 0.44
HR 66.9 66.6 0.28 [1.98; 1.42] 0.75
Weight 84.5 84.5 0.06 [0.08; 0.20] 0.38
After a large meal SBP 111.9 111.0 0.93 [3.65; 1.80] 0.50
DBP 67.2 66.1 1.09 [2.84; 0.66] 0.22
HR 66.4 67.7 1.30 [0.63; 3.22] 0.18
Weight 83.9 84.2 0.25 [0.07; 0.42] 0.006
Just after exercise SBP 112.4 114.3 1.84 [1.22; 4.90] 0.24
DBP 67.8 66.7 1.10 [2.66; 0.45] 0.16
HR 66.6 69.5 2.91 [1.20; 4.61] 0.001
Weight 83.4 83.4 0.03 [0.10; 0.16] 0.65
When hungry SBP 110.4 111.7 1.29 [1.50; 4.09] 0.36
DBP 66.1 67.0 0.84 [0.77; 2.46] 0.30
HR 66.6 66.9 0.30 [1.52; 2.13] 0.74
Weight 83.7 83.7 0.02 [0.11; 0.14] 0.82
After skipping a medication dose other than diuretics SBP 111.2 112.7 1.52 [0.97; 4.02] 0.23
DBP 68.5 68.2 0.33 [2.13; 1.48] 0.72
HR 66.5 68.2 1.78 [0.34; 3.21] 0.02
Weight 84.2 84.4 0.12 [0.01; 0.25] 0.06
While listening to relaxing music SBP 111.7 109.7 1.97 [4.19; 0.25] 0.08
DBP 67.7 66.3 1.41 [2.95; 0.13] 0.07
HR 67.0 66.9 0.09 [1.61; 1.44] 0.91
Weight 84.1 84.2 0.10 [0.04; 0.24] 0.16
After shower/bath SBP 111.0 113.7 2.76 [0.12; 5.63] 0.06
DBP 67.0 66.5 0.47 [2.21; 1.27] 0.59
HR 67.8 66.9 0.92 [2.60; 0.77] 0.28
Weight 84.5 84.6 0.05 [0.07; 0.16] 0.41
SBP, systolic blood pressure (mmHg); DBP, diastolic blood pressure (mmHg); HR, heart rate (bpm); Weight (kg).
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were given a calendar of interventions scheduling activities
approximately twice a week; activities included taking salty
food, skipping a dose of diuretic or other HF medication, lis-
tening to loud and irritating noise or relaxing music, drinking
tea or coffee, taking a large meal, being hungry, exercise, or
bathing. Patients were asked to measure their vital signs after
these extra activities. All patients signed an informed con-
sent. The study complied with the requirements of the decla-
ration of Helsinki and was approved by the ethics committee
of each participating hospital.
Statistical differences between the day before the action
and the day of the action were assessed using mean compar-
ison for paired data. Statistical analyses were performed with
SPSS 15 (SPSS Inc., Chicago, IL, USA). A two-sided P-value of
<0.05 was considered signiﬁcant.
Results
A total of 123 patients were enrolled in the HF Trial after con-
ﬁrmation of the inclusion criteria and informed consent signing.
Of the 100 patients that ﬁnally started the ﬁrst phase of the
trial, 76 reached Phase C (Figure 2). They (n = 76) had a mean
age of 76± 10.8 years, 75% were male, with mean NT-proBNP
values of 4729± 5339pg/mL, mainly in NYHA class II/III
(31.6%/65.8%) and from ischaemic aetiology cause (55.3%).
Other frequent HF aetiologies were idiopathic cardiomiopathy
(27.6%) and valvular and hypertensive origin (2.6% and 1.3%).
Main results of the 1200 activities performed by the 60 pa-
tients that fulﬁlled Phase C ﬁnal visit are collected in Table 1
(two patients were non-evaluable because of missing data).
Eating salty food or a large meal were the activities that
had a signiﬁcant impact on weight gain (+0.3 kg; P< 0.001
and P = 0.006, respectively). Skipping a medication dose other
than diuretics also showed a tendency on increasing patient’s
weight (P = 0.059). In contrast, weight gain after skipping a
dose of diuretic had a P-value of 0.1.
Exercise increased HR, on average +3 bpm, P = 0.001. Skip-
ping adose ofmedication other thatdiuretics also had aneffect
on HR, but more modest: almost +2 bpm, P = 0.016. Skipping a
doseofdiuretic showedatendencyon increasingHR(P = 0.087).
There were no statistically signiﬁcant changes on measured
vitalsignsforbeneﬁcialactivitiessuchaslisteningtorelaxingmu-
sic, but this activity showeda tendencyon lowering systolic and
diastolicbloodpreassure (P = 0.081andP = 0.071, respectively).
Eating salty food lowered diastolic blood preassure (P = 0.05).
No differences in vital signs were observed the day after
any of the activities were performed.
Conclusions
The Motiva telehealth system has previously shown to
signiﬁcantly reduce the number of hospitalizations and
days in hospital for HF and other cardiac causes in the
CARME-study.6 It has also shown to satisfy patients that used
it and to change patients’ behaviours.7 In the present study,
we were able to prove that this system is capable of
detecting variations of vital signs values (even small ones)
because of life routine alterations.
One of the reasons proposed for lack of patient’s self-
monitoring is the gradual loss of motivation and the tedious-
ness of routine. Telemonitoring is a promising approach that
could empower patients with HF and allow them to take a
much more active part in their own management.4 As a visual
tool for the patient, it may be useful for their motivation and
self care. The MOTIVA system provides an instant, graphic,
and visual feedback of self-measurements that can promote
compliance with health and dietary measures as the patient
can acknowledge how a deviation from the ‘good path’ alters
vital signs. It allows a greater awareness of how variations in
daily activities have an impact on parameters such as weight,
BP, or HR. This could reinforce the idea of medication and life-
style recommendation beneﬁts in cases of low-adherence.
Our study has several limitations: on one hand, the inher-
ent to an observational study with no control group; on the
other, we have no way to prove that patients did the
activities as they were not watched in situ. Some may have
lied about their compliance as suspected by some of the
clinicians, but according to our results, the compliance seems
to be high as the system was able to detect the changes.
In conclusion, our HTM system was able to detect small
changes in vital signs related to these activities. Whether in-
dividual patient variability in the response to these or other
interventions has implications for treatment or prognosis re-
mains to be explored. Further studies should assess if provid-
ing such a schedule of activities might be useful for patient
education and could improve long-term adherence to HTM.
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